Understand referral pathways in healthcare, from GP assessment to specialist care, including triage, patient flow, and system efficiency.
Decisions made by regulators, governments, and health authorities have a major impact on rare disease research, diagnosis, and access to treatment. This section explains the policies and regulatory frameworks that shape how medicines are approved, how clinical trials are run, and how healthcare systems decide which treatments are available to patients.
Articles cover topics such as orphan drug designation, approval pathways, health technology assessment, reimbursement decisions, international guidelines, and changes in national or global health policy.
We also report on recent regulatory decisions, consultations, and legislative updates that may affect patients, researchers, charities, and industry. The aim is to provide clear, evidence-based explanations of complex rules and processes, so readers can understand how policy and regulation influence real-world outcomes in rare disease.
How Referral Pathways Work
Understand referral pathways in healthcare, from GP assessment to specialist care, including triage, patient flow, and system efficiency.
The Down Syndrome Act: A Global Blueprint?
The UK's Down Syndrome Act is a global case study in turning fragmented services into coordinated care, offering lessons for rare disease policy worldwide.
Rare Disease as a Systems Challenge: Policy, Data, and Care
Explore rare disease as a systems challenge shaped by governance, data, and care design. See why long horizon, integrated approaches improve outcomes.
Ethical Challenges In Rare Disease Research
Learn how rare disease research challenges traditional ethics, including issues around patient recruitment, vulnerability, and regulatory oversight.
The Diagnostic Odyssey: Why Rare Diseases Are Hard to Identify
The diagnostic odyssey in rare diseases often takes 4–5 years. Discover why symptom overlap, misdiagnosis, system barriers, and genetic limits cause delays, plus emerging solutions.
How Health Policy Shapes Access to Rare Disease Treatments
Explore shifts in rare disease policy and how they impact patient access to life-saving orphan drugs.
What Prevalence and Incidence Mean and Why the Difference Matters
Understanding the difference between prevalence and incidence is key to interpreting health data, planning care, and supporting rare disease communities.
FDA's New Breakthrough Pathways for Rare Disease Treatments
A clear overview of the FDA’s new 2025 pathways transforming rare disease drug development, including RDEP, guidance updates, and mechanism based approval.